瑞巴派特治疗胃溃疡的临床疗效观察

目的观察瑞巴派特治疗胃溃疡的疗效。方法将69例胃溃疡患者随机分成2组：试验组35例,在雷贝拉唑和阿莫西林治疗基础上加用瑞巴派特口服,0.1g/次,3次/d 对照组34例,在雷贝拉唑和阿莫西林治疗基础上加用铝碳酸镁口服,1.0g/次,3次/d。均治疗8周。治疗前及治疗2、4、6、8周对患者上腹痛、上腹胀、反酸和嗳气症状进行症状评分,治疗前、后分别行胃镜检查及胃黏膜组织病理学检查,并进行胃镜下疗效评分和胃黏膜慢性炎症程度、炎症活动程度评分。结果治疗后2组患者上腹痛、上腹胀、反酸和嗳气总积分间差别有统计学意义（P〈0.05） 胃镜评分间比较,差别无显著性意义（P〉0.05） 胃黏膜糜烂区慢性炎症程度及炎症活动程度评分间差别有统计学意义（P〈0.05）。结论瑞巴派特治疗胃溃疡有良好的疗效。

Clinicial Observation of the Therapeutic Effect of Rebamipide on Gastric Ulcer

Objective To investigate the therapeutic effect of Rebamipide on gastric ulcer.Methods 69 patients with gastric ulcer were randomly divided into 2 groups.35 cases in the treatment group were given Rebamipide orally,0.1g each time,3 times a day.34 cases in the control group were given Hydrotalcite orally,1.0g each time,3 times a day.Both groups were treated on the basis of Rabeprazole and Amoxicillin,course of treatment is 8 successive weeks.The symptoms of upper abdominal pain,epigastric distention,sour regurgitation,and belching were assessed before and 2,4,6,8 weeks after the treatment.Gastroscopic and gastric mucosal histopathologic examination was applied before and after the treatment,then the therapeutic effect of the treatment and the chronic inflammatory activity as well as its severity of the gastric mucosa were assessed.Results The general integral calculus difference was significant as for the symptoms of upper abdominal pain,epigastric distention,sour regurgitation,and belching after the treatment（P0.05）.There was not significant difference in gastroscopic scoring（P0.05）.The scores of chronic inflammatory activity and its severity of the erosive gastric mucosa were statistically significant（P0.05）.Conclusion The curative effect of Rebamipide has a good effect treatment on the gastric ulcer patients.